These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36189235)

  • 1. Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library.
    Dormeshkin D; Shapira M; Dubovik S; Kavaleuski A; Katsin M; Migas A; Meleshko A; Semyonov S
    Front Immunol; 2022; 13():965446. PubMed ID: 36189235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.
    Li Q; Humphries F; Girardin RC; Wallace A; Ejemel M; Amcheslavsky A; McMahon CT; Schiller ZA; Ma Z; Cruz J; Dupuis AP; Payne AF; Maryam A; Yilmaz NK; McDonough KA; Pierce BG; Schiffer CA; Kruse AC; Klempner MS; Cavacini LA; Fitzgerald KA; Wang Y
    Front Immunol; 2022; 13():995412. PubMed ID: 36172366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants.
    Yang ML; Yuan TZ; Chan KY; Ding L; Han Z; Franco H; Holliday C; Kannan S; Davidson E; Doranz BJ; Chandran K; Miller EH; Plante JA; Weaver SC; Cho E; Kailasan S; Marsalek L; Giang H; Abdiche Y; Sato AK
    Antib Ther; 2024 Apr; 7(2):164-176. PubMed ID: 38933534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
    Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
    BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
    Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
    Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; da Fonseca Rezende E Mello J; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley TB; Hsu A; Dandey V; Sharma K; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    PLoS One; 2022; 17(8):e0272364. PubMed ID: 35947606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobody engineering for SARS-CoV-2 neutralization and detection.
    Hannula L; Kuivanen S; Lasham J; Kant R; Kareinen L; Bogacheva M; Strandin T; Sironen T; Hepojoki J; Sharma V; Saviranta P; Kipar A; Vapalahti O; Huiskonen JT; Rissanen I
    Microbiol Spectr; 2024 Apr; 12(4):e0419922. PubMed ID: 38363137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.
    Ma H; Zeng W; Meng X; Huang X; Yang Y; Zhao D; Zhou P; Wang X; Zhao C; Sun Y; Wang P; Ou H; Hu X; Xiang Y; Jin T
    J Virol; 2021 Apr; 95(10):. PubMed ID: 33658349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into the rational design of a nanobody that binds with high affinity to the SARS-CoV-2 spike variant.
    Yamaguchi K; Anzai I; Maeda R; Moriguchi M; Watanabe T; Imura A; Takaori-Kondo A; Inoue T
    J Biochem; 2023 Feb; 173(2):115-127. PubMed ID: 36413757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.
    Stefan MA; Light YK; Schwedler JL; McIlroy PR; Courtney CM; Saada EA; Thatcher CE; Phillips AM; Bourguet FA; Mageeney CM; McCloy SA; Collette NM; Negrete OA; Schoeniger JS; Weilhammer DR; Harmon B
    MAbs; 2021; 13(1):1958663. PubMed ID: 34348076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; Rezende E Mello JDF; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley T; Hsu A; Dandey V; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    bioRxiv; 2022 Mar; ():. PubMed ID: 34729560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.